Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial. Trial registration number: NCT02330926.
cachexia, trial
Solheim, Tora S.
68736e7c-aacf-4cae-92cd-fdced6e8eaa8
Laird, Barry J.A.
653f2715-90e5-420c-8282-d49d6f656212
Balstad, Trude R.
a58b5b5b-604c-4ad0-b924-ecf431f5b7fc
Bye, Asta
3582683f-50d5-47a3-8e59-c716dd92e9f6
Stene, Guro
76509db4-e5be-4b89-9afb-d8d02ee99a2c
Baracos, Vickie
a0cbf61c-c71c-4f7e-8b59-73ebb63b867b
Strasser, Florian
49413ada-f774-42d7-b42c-75028b4d79b1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maddocks, Matthew
33311e9a-383e-4824-8fed-524778230b1a
Fallon, Marie
67687167-b205-40ea-be26-00f8f57004f9
Kaasa, Stein
b114305b-4b07-4bdd-a651-b83c609da72c
Fearon, Kenneth
021154b0-9dc2-4bf0-ade9-891e2fe9a8fc
Solheim, Tora S.
68736e7c-aacf-4cae-92cd-fdced6e8eaa8
Laird, Barry J.A.
653f2715-90e5-420c-8282-d49d6f656212
Balstad, Trude R.
a58b5b5b-604c-4ad0-b924-ecf431f5b7fc
Bye, Asta
3582683f-50d5-47a3-8e59-c716dd92e9f6
Stene, Guro
76509db4-e5be-4b89-9afb-d8d02ee99a2c
Baracos, Vickie
a0cbf61c-c71c-4f7e-8b59-73ebb63b867b
Strasser, Florian
49413ada-f774-42d7-b42c-75028b4d79b1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Maddocks, Matthew
33311e9a-383e-4824-8fed-524778230b1a
Fallon, Marie
67687167-b205-40ea-be26-00f8f57004f9
Kaasa, Stein
b114305b-4b07-4bdd-a651-b83c609da72c
Fearon, Kenneth
021154b0-9dc2-4bf0-ade9-891e2fe9a8fc
Solheim, Tora S., Laird, Barry J.A., Balstad, Trude R., Bye, Asta, Stene, Guro, Baracos, Vickie, Strasser, Florian, Griffiths, Gareth, Maddocks, Matthew, Fallon, Marie, Kaasa, Stein and Fearon, Kenneth
(2018)
Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial.
BMJ Supportive & Palliative Care.
(doi:10.1136/bmjspcare-2017-001440).
Abstract
Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial. Trial registration number: NCT02330926.
This record has no associated files available for download.
More information
Accepted/In Press date: 13 December 2017
e-pub ahead of print date: 9 February 2018
Keywords:
cachexia, trial
Identifiers
Local EPrints ID: 425379
URI: http://eprints.soton.ac.uk/id/eprint/425379
ISSN: 2045-435X
PURE UUID: 5ec555e1-c09a-432e-809e-461581f70277
Catalogue record
Date deposited: 16 Oct 2018 16:30
Last modified: 16 Mar 2024 04:19
Export record
Altmetrics
Contributors
Author:
Tora S. Solheim
Author:
Barry J.A. Laird
Author:
Trude R. Balstad
Author:
Asta Bye
Author:
Guro Stene
Author:
Vickie Baracos
Author:
Florian Strasser
Author:
Matthew Maddocks
Author:
Marie Fallon
Author:
Stein Kaasa
Author:
Kenneth Fearon
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics